Slide 1: Q1 2026 Earnings Presentation
BRUKER CORPORATION (NASDAQ: BRKR) Q1 2026 Earnings Presentation May 6, 2026 Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Joe Kostka, Director, Investor Relations
Slide 2: Safe Harbor Statement
BRUKER CORP ORATI ON Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 193
Slide 3: Business Update
Q1 2026 Business Update 3
Slide 4: Q1 2026: Organic Revenue, Non-GAAP Margins and EPS Decline; Performance Better than Expected
Q1 2026: Organic Revenue, Non-GAAP Margins and EPS Decline; Performance Better than Expected; Strong BSI Bookings Growth in Q1 Q1 2026 Performance; Year-over-Year Changes Q1 Financials ❖ Revenue increase of $22M, or 2.7% Revenues [$M] ▪ Organic decline 4.4%, with BSI down 5% and BEST up 3% ▪ M&A con
Slide 5: Bruker Group Q1 2026 CER Revenue and Bookings Performance (yoy)
GROUP OVERVIEW Bruker Group Q1 2026 CER Revenue and Bookings Performance (yoy) Bruker BIOSPIN Group ▪ BIOSPIN CER revenue down high-single digits % ▪ Revenue growth in Pre-Clinical Imaging systems, Service and SciY software; more than offset by weakness in NMR systems due to soft aca/gov revenues in
Slide 6: Bruker Group Q1 2026 CER Revenue and Bookings Performance (yoy)
GROUP OVERVIEW Bruker Group Q1 2026 CER Revenue and Bookings Performance (yoy) Bruker NANO Group ▪ NANO CER revenue down mid-single digits % ▪ Weak revenues in aca/gov and industrial ▪ Strong Q1-26 orders, including in X-ray industrial research tools and spatial biology ▪ Strong AI-driven orders for
Slide 7: NMR Innovations at ENC 2026: Research and Pharma Markets
IN N OVATION EN G IN E NMR Innovations at ENC 2026: Research and Pharma Markets NMRtist AI-assisted protein NMR structure elucidation, also for non-NMR-experts New Fourier 80 Duo Advanced Chemical Profiling 2.0: automated 80 MHz as affordable standard: multicomponent quantification for benchtop and
Slide 8: Innovations at AGBT & AACR: Best-in-Class Spatial Biology for Capturing Complexity of Disease Biology
IN N OVATION EN G IN E Innovations at AGBT & AACR: Best-in-Class Spatial Biology for Capturing Complexity of Disease Biology Launch of PaintScape Launch of CellScape XR Multiplexed Direct Visualization of Genome Quantitative Spatial Proteomics Unprecedented in situ 3D genome studies: Next-gen spatia
Slide 9: Innovations at ESCMID: Higher-Throughput Sample-to-Answer MDx; Novel Microbial ID and Outbreak Management Workflows
IN N OVATION EN G IN E Innovations at ESCMID: Higher-Throughput Sample-to-Answer MDx; Novel Microbial ID and Outbreak Management Workflows MALDI Biotyper Workflow and MyGenius PRO Identification Enhancements ▪ S2A MDx qPCR system with higher throughput to ▪ New Easy T Kit for consistent sample trans
Slide 10: Financial Update
Q1 2026 Financial Update 10
Slide 11: Q1 2026 Selected Non-GAAP Financial Measures
Q1 2026 YEAR-OVER-YEAR COMPARISON Q1 2026 Selected Non-GAAP Financial Measures1 [$ m, except EPS] Q1 2026 Q1 2025 Δ Comments (year-over-year) Total Revenues 823.4 801.4 2.7% ▪ Revenue increase of 2.7% Gross Profit 411.8 410.9 0.2% ▪ BSI organic revenue decrease of 5%; BEST 3% Margin (% of revenues)
Slide 12: Q1 2026 Selected Cash Flow And Balance Sheet Measures
Q1 YEAR-OVER-YEAR COMPARISON Q1 2026 Selected Cash Flow And Balance Sheet Measures [$M] Q1 2026 Q1 2025 Δ Comments (year-over-year) GAAP Net Income 15.7 16.8 (1.1) Depreciation & amortization 58.3 50.4 7.9 ▪ Free cash flow up $8M, on higher operating Changes in working capital 10.6 14.8 (4.2) cash f
Slide 13: FY 2026 Outlook
C20) os ae - FY 2026 Outlook Vi,
Slide 14: Reconfirming FY 2026 Financial Outlook (as of May 6, 2026)
Reconfirming FY 2026 Financial Outlook (as of May 6 , 2026) th FY 2026 Guidance (year-over-year %s) Non-GAAP Assumptions & YoY Estimates Revenue $3.57B to $3.60B ▪ FY26 organic revenue growth of 1–2% Reported Revenue Growth +4% to +5% Organic revenue growth +1% to +2% ▪ FY26 operating margin up 250-
Slide 15: Supplementary Financial Information
Supplementary Financial Information* * For preliminary financial statements, GAAP to Non-GAAP reconciliations, and other supplementary financial information, please refer to our Q1 2026 Earnings Press Release issued May 6th, 2026. 15
Slide 16: ;
;